Lymph Node Microenvironment Modifications in Patients with CLL Treated with Venetoclax-based regimens

Status

Suspended

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515938-32-00

Enrollment

Registered

2024-11-19

Start date

2022-08-04

Completion date

Unknown

Last updated

2024-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Lymphocytic Leukemia

Brief summary

Characterization by immunohistochemistry, gene expression profile, protein expression and proliferative activity of CLL lymphocytes and LN-derived accessory cells of CLL patients treated with venetoclax-based regimens 12 months after completion of the venetoclax ramp-up phase, Definition of ultrasound characteristics of LNs in CLL patients treated with venetoclax-based regimens 12 months after completion of the venetoclax acceleration phase

Interventions

DRUGVENETOCLAX

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Characterization by immunohistochemistry, gene expression profile, protein expression and proliferative activity of CLL lymphocytes and LN-derived accessory cells of CLL patients treated with venetoclax-based regimens 12 months after completion of the venetoclax ramp-up phase, Definition of ultrasound characteristics of LNs in CLL patients treated with venetoclax-based regimens 12 months after completion of the venetoclax acceleration phase	—

Measure

Time frame

—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026